Advertisement

Drugs

, Volume 79, Issue 13, pp 1467–1475 | Cite as

Polatuzumab Vedotin: First Global Approval

  • Emma D. DeeksEmail author
AdisInsight Report

Abstract

Polatuzumab vedotin (polatuzumab vedotin-piiq; Polivy™) is an antibody–drug conjugate comprising a monoclonal antibody against CD79b (a B cell receptor component) covalently conjugated to the anti-mitotic cytotoxic agent monomethyl auristatin (MMAE) via a cleavable linker. After binding to CD79b on the B-cell surface, polatuzumab vedotin is internalized and the linker is cleaved, releasing MMAE into the cell, where it inhibits division and induces apoptosis. Polatuzumab vedotin is being developed by Genentech (a subsidiary of Roche) for the treatment of haematological malignancies. In June 2019, the US FDA granted accelerated approval to polatuzumab vedotin, in combination with bendamustine plus rituximab, for the treatment of adults with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who have received at least two prior therapies. Use of the compound in combination with bendamustine plus rituximab is also under regulatory review for relapsed/refractory DLBCL in the EU and is in ongoing phase 1b/2 development in this setting or relapsed/refractory follicular lymphoma (FL) in several countries. Various other polatuzumab vedotin combination therapy regimens are also in phase 1b/2 development for relapsed/refractory non-Hodgkin lymphoma (NHL) [including DLBCL and FL] or in phase 2 or 3 development for previously untreated DLBCL, while polatuzumab vedotin monotherapy has been in phase 1 development for relapsed/refractory B-cell NHL in Japan. This article summarizes the milestones in the development of polatuzumab vedotin leading to this first approval for its use in combination with bendamustine plus rituximab for relapsed/refractory DLBCL.

Notes

Compliance with Ethical Standards

Funding

The preparation of this review was not supported by any external funding.

Conflict of interest

During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Emma Deeks is a salaried employee of Adis International Ltd/Springer Nature, is responsible for the article content and declares no relevant conflicts of interest.

References

  1. 1.
    ADC Review. What are antibody-drug conjugates (ADCs)? J Antibody Drug Conjugates. 2019. https://www.adcreview.com/the-review/antibody-drug-conjugates/what-are-antibody-drug-conjugates/. Accessed 28 Jun 2019.
  2. 2.
    The Human Protein Atlas. CD79B. 2019. https://www.proteinatlas.org/ENSG00000007312-CD79B/pathology. Accessed 28 June 2019.
  3. 3.
    Genentech Inc. Polivy™ (Polatuzumab vedotin-piiq) for injection, for intravenous use: US Prescribing Information. 2019. https://www.fda.gov. Accessed 28 June 2019.
  4. 4.
    U.S. Food and Drug Administration. FDA approves polatuzumab vedotin-piiq for diffuse large B-cell lymphoma. 2019. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-polatuzumab-vedotin-piiq-diffuse-large-b-cell-lymphoma. Accessed 28 Jun 2019.
  5. 5.
    Seattle Genetics Inc. Seattle Genetics announces antibody-drug conjugate agreement with Genentech [media release]. 22 Apr 2002. http://www.seattlegenetics.com.
  6. 6.
    Seattle Genetics, Inc. Seattle Genetics establishes preferred antibody-drug conjugate manufacturing relationship with Albany Molecular Research, Inc [media release]. 13 Jul 2004. http://www.seattlegenetics.com/.
  7. 7.
    Seattle Genetics. Seattle Genetics receives additional $10 million from Genentech under antibody-drug conjugate collaboration [media release]. 19 Dec 2003. http://www.seattlegenetics.com.
  8. 8.
    Seattle Genetics, Inc. Seattle Genetics and Genentech expand antibody-drug conjugate collaboration [media release]. 9 Nov 2004. http://www.seattlegenetics.com.
  9. 9.
    Seattle Genetics, Inc. Seattle Genetics announces extension of antibody-drug conjugate collaboration with Genentech [media release]. 28 Mar 2007. http://www.seattlegenetics.com.
  10. 10.
    Seattle Genetics, Inc. Seattle Genetics to receive $9.5 million payment from Genentech to extend antibody-drug conjugate collaboration [media release]. 20 Apr 2010. http://www.seattlegenetics.com.
  11. 11.
    Seattle Genetics, Inc. Seattle Genetics expands antibody-drug conjugate collaboration with Genentech [media release]. 3 Aug 2010. http://www.seattlegenetics.com.
  12. 12.
    Pfeifer M, Zheng B, Erdmann T, et al. Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes. Leukemia. 2015;29(7):1578–86.CrossRefPubMedGoogle Scholar
  13. 13.
    Tiwari AA, Ayello J, Van De Ven C, et al. Antibody drug conjugates (anti-CD79b-vc-MMAE, polatuzumab vedotin) exhibit enhanced cell death targeted to CD79b + Burkitt lymphoma (BL) and primary mediastinal large B-cell lymphoma (PMBL) [abstract no. 579]. Cancer Res. 2016;76(14 Suppl).  https://doi.org/10.1158/1538-7445.AM2016-579.
  14. 14.
    Tiwari AA, Edani D, Azmy C, et al. Enhanced in vitro/in vivo cytotoxicity against Burkitt lymphoma/primary mediastinal large B cell lymphoma by polatuzumab vedotin (hu-anti-CD79b-vc-MMAE, PV) alone or in combination with obinutuzumab [abstract no. 1788]. Cancer Res. 2018;78(13 Suppl).  https://doi.org/10.1158/1538-7445.AM2018-1788.
  15. 15.
    Amin DN, Oeh J, Zindal A, et al. Anti-tubulin antibody drug conjugates potentiate venetoclax activity in non-Hodgkin lymphoma by targeting MCL-1 [abstract no. 880]. Cancer Res. 2018;78(13 Suppl).  https://doi.org/10.1158/1538-7445.AM2018-880.
  16. 16.
    Tiwari A, Edani D, Ayello J, et al. Polatuzumab vedotin alone or in combination with obinutuzumab synergistically enhances in vitro cytotoxicity and cytokine release against CD20 +/CD79B + burkitt lymphoma (BL)/primary mediastinal large B cell lymphoma (pmbl) [abstract]. Blood. 2017;130(Suppl 1):1540.Google Scholar
  17. 17.
    Lu D, Girish S, Marchand M, et al. Concentration-QTc analysis of polatuzumab vedotin in patients with B-cell hematologic malignancies [abstract no. PC-02]. Clin Pharmacol Ther. 2016;99(S1):S5.Google Scholar
  18. 18.
    Lu D, Jin JY, Gibiansky L, et al. Exposure-response analysis to assist selection of dose and treatment duration for polatuzumab vedotin as a single agent or in combination with rituximab for the treatment of B-cell lymphoma [abstract]. Blood. 2015;126(23):1525.Google Scholar
  19. 19.
    Shi R, Lu T, Ding H, et al. Ethnicity sensitivity assessment of polatuzumab vedotin pharmacokinetics in relapsed-refractory non-hodgkin lymphoma [abstract no. PII-102]. Clin Pharmacol Ther. 2019;105(S1):S71.Google Scholar
  20. 20.
    Lu D, Jin JY, Gibiansky L, et al. Population pharmacokinetics and exposure-response assessment of anti-CD79B antibody drug conjugate in patients: interim analysis results [abstract no. PII-095]. Clin Pharmacol Ther. 2015;97(S1):S88-9.Google Scholar
  21. 21.
    Shemesh CS, Agarwal P, Lee C, et al. Pharmacokinetics and drug interaction potential of polatuzumab vedotin in combination with R/G-CHP in patients with B-cell non-hodgkin lymphoma [abstract no. PII-101]. Clin Pharmacol Ther. 2019;105(S1):S71Google Scholar
  22. 22.
    Agarwal P, Lu D, Samineni D, et al. Clinical pharmacokinetics (PK) of polatuzumab vedotin (Pola) in combination with rituximab (R), obinutuzumab (G), cyclophosphamide (C), doxorubicin (H) and bendamustine (B) in 1 L or relapsed/refractory (R/R) non-Hodgkin’s lymphoma (NHL) patients [abstract no. 283]. Pharmacother. 2017;37(12):e203.Google Scholar
  23. 23.
    Palanca-Wessels MC, Czuczman M, Salles G, et al. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study. Lancet Oncol. 2015;16(6):704–15.CrossRefPubMedGoogle Scholar
  24. 24.
    Morschhauser F, Flinn IW, Advani R, et al. Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS). Lancet Haematol. 2019;6(5):e254–65.CrossRefPubMedGoogle Scholar
  25. 25.
    Phillips T, Brunvand M, Chen A, et al. Polatuzumab vedotin combined with obinutuzumab for patients with relapsed or refractory non-hodgkin lymphoma: preliminary safety and clinical activity of a phase Ib/II study [abstract]. Blood. 2016;128(22):622.Google Scholar
  26. 26.
    Matasar M, Herrera AF, Kamdar M, et al. Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed/refractory follicular lymphoma or diffuse large B-cell lymphoma: updated results of a phase 1B/2 study [abstract no. S468]. Haematologica. 2017;102(s2):173.Google Scholar
  27. 27.
    Sehn LH, Herrera AF, Matasar MJ, et al. Polatuzumab vedotin (POLA) plus bendamustine (B) with rituximab (R) or obinutuzumab (G) in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): updated results of a phase (PH) IB/II study [abstract]. Blood. 2018;132(Suppl 1):1683.Google Scholar
  28. 28.
    McMillan A, Sehn L, Herrera A, et al. Updated results from a phase Ib/II study in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) treated with polatuzumab vedotin (Pola) plus bendamustine (B) with rituximab (R) or obinutuzumab (G) [abstract no. BSH19-PO-079]. Br J Haematol. 2019;185(S1):80.Google Scholar
  29. 29.
    Sehn LH, Kamdar M, Herrera AF, et al. Randomized phase 2 trial of polatuzumab vedotin (Pola) with bendamustine and rituximab (BR) in relapsed/refractory (r/r) FL and DLBCL [abstract no. 7507]. J Clin Oncol. 2018;36(15 Suppl).Google Scholar
  30. 30.
    Sehn LH, Kamdar M, Herrera AF, et al. Adding polatuzumab vedotin (POLA) to bendamustine and rituximab (BR) treatment improves survival in patients with relapsed/refractory dlbcl: results of a phase 2 clinical trial [abstract no. S802]. HemaSphere. 2018;2(S1):348–9.Google Scholar
  31. 31.
    Tilly H, Morschhauser F, Bartlett NL, et al. Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b-2 study. Lancet Oncol. 2019.  https://doi.org/10.1016/s1470-2045(19)30091-9.CrossRefPubMedGoogle Scholar
  32. 32.
    Forero-Torres A, Kolibaba KS, Tilly H, et al. Polatuzumab vedotin combined with obinutuzumab, cyclophosphamide, doxorubicin, and prednisone (G-CHP) for patients with previously untreated diffuse large b-cell lymphoma (DLBCL): updated results of a phase IB/II study [abstract]. Blood. 2017;130(Suppl 1):4120.Google Scholar
  33. 33.
    Bartlett NL, Chen AI, Kolibaba KS, et al. Polatuzumab vedotin combined with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for patients with previously untreated diffuse large b-cell lymphoma (DLBCL): preliminary results of a phase Ib dose-escalation. Blood. 2015;126(23):2726.Google Scholar
  34. 34.
    Tilly H, Sharman J, Bartlett N, et al. Pola-R-CHP: polatuzumab vedotin combined with rituximab, cyclophosphamide, doxorubicin, prednisone for patients with previously untreated diffuse large B-cell lymphoma [abstract no. S106]. Haematologica. 2017;102(s2):4.Google Scholar
  35. 35.
    Tilly H, Morschhauser F, Bartlett NL, et al. Polatuzumab vedotin combined with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for patients with previously untreated diffuse large B-cell lymphoma (DLBCL): updated results of a phase Ib/II study [abstract]. Blood. 2016;128(22):1853.Google Scholar
  36. 36.
    Diefenbach C, Kahl B, Banerjee L, et al. Polatuzumab vedotin (Pola) + obinutuzumab (G) and lenalidomide (Len) in patients (pts) with relapsed/refractory (R/R) follicular lymphoma (FL): interim analysis of a phase Ib/II trial [abstract no. 7505]. J Clin Oncol. 2019;37(15 Suppl).Google Scholar
  37. 37.
    Hatake K, Kinoshita T, Terui Y, et al. A phase I pharmacokinetic and safety study of polatuzumab vedotin in Japanese patients with relapsed/refractory B-cell non-Hodgkin lymphoma: a comparison with non-Japanese DCS4968 g study [abstract no. e19070]. J Clin Oncol. 2016;34(15 Suppl).Google Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Springer NatureAucklandNew Zealand

Personalised recommendations